Trial Profile

Phase Ib/II investigator-sponsored trial evaluatin the safety and preliminary efficacy of WEE1 inhibitor Debio 0123 in combination with Sacituzumab Govitecan (Trodelvy®) in triple-negative and HR+/HER2- advanced breast cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab govitecan (Primary) ; Zedoresertib Debiopharm (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions
Acronyms WIN-B
Sponsors Medica Scientia Innovation Research

29 May 2025 According to Debiopharm media release , data from this trial will be presented at the 2025 Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois.
25 Feb 2025 According to Debiopharm media release , WIN-B trial is sponsored by MEDSIR and fully funded by Debiopharm. Gilead Sciences, Inc. (Gilead) is providing supply of Trodelvy.
31 May 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com